Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study

Liu, Bangshan; Zhang, Yan; Zhang, Li; Li, Lingjiang

doi:10.1186/s12888-014-0342-4

Table 1 Main characteristics of included RCTs

From: Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study

Study	Sample size (n)		Diagnosis	TRD definition	Medication regimen	rTMS parameters				Outcome assessment	Follow-up?	Adverse effects
	rTMS	sham				Frequency,Hz	Intensity (%MT)	Sessions	Total pulses
Garcia-Toro et al. [36]	17	18	DSM-IV MDD	Failed 2 or more ADs, 6 weeks minimum	continue current treatment	20	90	10	12000	HAMD-21	2w of an open trial	Scalp discomfort and slight headaches
Rossini et al. [38]	18	17	DSM-IV MDD & ≥ 26 in HAMD-21	Failed 2 or more ADs, 6 weeks minimum	continue current treatment	15	100	10	6000	HAMD-21	3w of follow up	Mild headache; discomfort at the site of stimulation
Rossini et al. [38]	19					15	80		6000
Garcia-Toro et al. [37]	10	10	DSM-IV MDD	Failed 2 or more ADs, 1 month minimum	continue current treatment	20,1	110	10	12000	HAMD-21	2w of follow up	Scalp discomfort and headaches
Garcia-Toro et al. [37]	10					20,1	110		12000
Bretlau et al. [27]	22	23	DSM-IV MDD	Failed 2 or more ADs, 6 weeks minimum	Escitalopram from 10 mg/d to 20 mg/d	8	90	15	19200	HAMD-17	9w of follow up	Reduced sleep length and greater concentration difficulties (sham group)
Martinot et al. [39]	16	14	DSM-IV-R MDD& ≥18 in MADRS & ≥16 in HAMD	Failed 2 or more ADs, 4 weeks minimum	minimal and stable dosage of previous treatment	10	90	10	16000	HAMD-21	N	Not mentioned
Martinot et al. [39]	18					10	90		16000
Bakim et al. [30]	12	12	DSM-IV MDD & ≥18 in MADRS & ≥20 in HAMD	Failed 2 or more ADs, 6 weeks minimum	continue current treatment	20	80	30	24000	HAMD-17	N	Mild headache and mild discomfort
Bakim et al. [30]	11					20	100		24000
Chen et al. [35]	10	11	DSM-IV MDD & ≥ 18 in HAMD-17	Failed 2 or more ADs, 6 weeks minimum	continue current treatment, stable dose	20	90	10	8000	HAMD-17	9w of follow up	Not mentioned(1 dropouts for unspecific somatic complaints, sham group)

Back to article page

ISSN: 1471-244X

Contact us

Submission enquiries: bmcpsychiatry@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Psychiatry

Contact us